Table 4.
Grade 3–4 toxicity in irinotecan treated colorectal cancer cases, by UGT1A1*28 genotype
| 6/6 | 6/7 | 7/7 | ALL | P for trend | |
|---|---|---|---|---|---|
| n=91 | n=98 | n=25 | n=214 | ||
| Grade 3–4 Toxicity | |||||
| Hematological n (%) | 7 (7.7%) | 10 (10.2%) | 12 (48.0%) | 29 (13.6%) | P<=0.001 |
| Leucopenia % | 6.6% | 6.1% | 32% | 9.3% | P=0.005 |
| Neutropenia % | 5.5% | 8. 2% | 24.0% | 8.9% | P=0.019 |
| Neutropenic fever % | 0 | 2.0% | 24.0% | 3.7% | P<=0.001 |
| Non –hematological n (%) | 31 (34.1%) | 29 (29.6%) | 7 (28%) | 67 (31.3%) | P=0.46 |
| Diarrhea % | 27.5% | 18..4% | 20% | 22.4% | P=0.20 |
| Vomiting % | 4.4% | 12.2% | 20% | 9.8% | P=0.015 |
| Infection % | 4.4% | 7.1% | 0 | 5.1% | P=0.82 |
| Mucositis % | 2.2% | 1% | 0 | 1.4% | P=0.73 |
| Time to toxicity (weeks) Median (IR) | 5.9(2.1–8.6) | 3.2(2.1–5.9) | 2.1(1.2–3.1) | 3.1 (2–6.9) | P=0.016 |
| Hospitalization due to toxicity | |||||
| Yes n (%) | 13 (14.4) | 24 (25.3%) | 11 (45.8%) | 48 (23%) | P=0.001 |
| unknown | 1 | 3 | 1 | ||
| Short-term death*(%) | 2.9% | 5.2% | 12.8% | 5.2% | P=0.027 |
*
within two months from treatment onset, based on all treated patients